Recro Pharma, a contract development and manufacturing organization (CDMO), announced on June 2, 2021 that it has expanded the clinical capabilities of its clinical trial services (CTS) offerings.
The added capabilities include clinical-scale sachet and blister packaging for clinical trial pharmaceuticals and a relationship with a European Union Qualified Person (QP) for its CTS offerings, the company said in a press release. Based on an audit completed by the QP, Recro meets the relevant GMP manufacturing standards and requirements for clinical trial materials to be used in the European Union.
